BRPI0720355B8 - Composições oftálmicas para o tratamento de presbiopia, bem como o uso das mesmas - Google Patents
Composições oftálmicas para o tratamento de presbiopia, bem como o uso das mesmasInfo
- Publication number
- BRPI0720355B8 BRPI0720355B8 BRPI0720355A BRPI0720355A BRPI0720355B8 BR PI0720355 B8 BRPI0720355 B8 BR PI0720355B8 BR PI0720355 A BRPI0720355 A BR PI0720355A BR PI0720355 A BRPI0720355 A BR PI0720355A BR PI0720355 B8 BRPI0720355 B8 BR PI0720355B8
- Authority
- BR
- Brazil
- Prior art keywords
- presbyopia
- treatment
- well
- ophthalmic compositions
- ophthalmic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06026169.0 | 2006-12-18 | ||
EP06026169A EP1938839B1 (en) | 2006-12-18 | 2006-12-18 | Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
PCT/IB2007/003780 WO2008075149A2 (en) | 2006-12-18 | 2007-12-06 | Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0720355A2 BRPI0720355A2 (pt) | 2013-12-31 |
BRPI0720355B1 BRPI0720355B1 (pt) | 2019-02-05 |
BRPI0720355B8 true BRPI0720355B8 (pt) | 2023-01-24 |
Family
ID=37969963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0720355A BRPI0720355B8 (pt) | 2006-12-18 | 2007-12-06 | Composições oftálmicas para o tratamento de presbiopia, bem como o uso das mesmas |
Country Status (13)
Country | Link |
---|---|
US (2) | US8524758B2 (pt) |
EP (1) | EP1938839B1 (pt) |
JP (1) | JP5769375B2 (pt) |
AT (1) | ATE439863T1 (pt) |
AU (1) | AU2007335919B2 (pt) |
BR (1) | BRPI0720355B8 (pt) |
CA (1) | CA2672985C (pt) |
DE (1) | DE602006008643D1 (pt) |
DK (1) | DK1938839T3 (pt) |
ES (1) | ES2329161T3 (pt) |
MX (1) | MX2009006505A (pt) |
PT (1) | PT1938839E (pt) |
WO (1) | WO2008075149A2 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
CA2849366C (en) | 2011-09-20 | 2019-09-10 | Juan Carlos Abad | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
CN104968308B (zh) * | 2012-02-25 | 2017-11-07 | 直焦光学股份有限公司 | 利用激光缩瞳术改善视力的装置和方法 |
US10744034B2 (en) * | 2012-04-25 | 2020-08-18 | Gregg S. Homer | Method for laser treatment for glaucoma |
US10507245B2 (en) * | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US9844537B2 (en) | 2013-08-28 | 2017-12-19 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US10617763B2 (en) | 2013-08-28 | 2020-04-14 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
US9833441B2 (en) | 2013-08-28 | 2017-12-05 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
US11179327B2 (en) | 2013-08-28 | 2021-11-23 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US10307408B2 (en) | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
US10064818B2 (en) | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
WO2015053829A1 (en) * | 2013-10-09 | 2015-04-16 | Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee | Methods and compositions for treating and preventing signs or symptoms of eye disease |
ES2538551B1 (es) * | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
US20170007637A1 (en) * | 2014-02-11 | 2017-01-12 | Orasis Pharmaceuticals Ltd. | Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration |
KR20180014825A (ko) | 2015-06-18 | 2018-02-09 | 프레스바이오피아 세라피스, 엘엘씨 | 눈의 굴절 이상 치료 및 원거리 시력 개선용 조성물 및 방법 |
US20190000808A1 (en) * | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
AU2017311636B2 (en) * | 2016-08-19 | 2023-08-10 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
US20180104508A1 (en) * | 2016-10-13 | 2018-04-19 | Ronald Michael Kurtz | Optical system for nonpharmacologic constriction of a pupil |
US10406352B2 (en) * | 2016-10-13 | 2019-09-10 | Ronald Michael Kurtz | System for temporary nonpharmacologic constriction of the pupil |
US20180104098A1 (en) * | 2016-10-13 | 2018-04-19 | Ronald Michael Kurtz | System for nonpharmacologic long-term constriction of a pupil |
US20180104099A1 (en) * | 2016-10-13 | 2018-04-19 | Ronald Michael Kurtz | Digitally controlled optical system for nonpharmacologic constriction of a pupil |
US10406380B2 (en) * | 2016-10-13 | 2019-09-10 | Ronald Michael Kurtz | Method for nonpharmacologic temporary constriction of a pupil |
PL3681500T3 (pl) * | 2018-04-24 | 2022-08-01 | Allergan, Inc. | Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności |
US20240000812A1 (en) * | 2020-11-13 | 2024-01-04 | Plex Pharmaceuticals, Inc. | Pharmacological agents for treating conditions of the eye |
US11648247B1 (en) | 2021-12-16 | 2023-05-16 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07508751A (ja) * | 1992-07-02 | 1995-09-28 | テラー・オフサルミック・ファーマシューティカルズ・インコーポレーテッド | 老視治療のための方法および生産品 |
US5422116A (en) * | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
US6263879B1 (en) | 1998-11-10 | 2001-07-24 | J. T. Lin | Treatment of presbyopia and other eye disorders using a scanning laser system |
US6258082B1 (en) | 1999-05-03 | 2001-07-10 | J. T. Lin | Refractive surgery and presbyopia correction using infrared and ultraviolet lasers |
US6540990B2 (en) * | 2000-09-22 | 2003-04-01 | Gerard M. Nolan | Physiological method of improving vision |
US6273092B1 (en) * | 2000-09-22 | 2001-08-14 | Gerard M. Nolan | Methods for treating various eye disorders |
US20050205101A1 (en) * | 2002-10-17 | 2005-09-22 | Lin J T | Combined pharmocological and surgical method and system for the treatment of eye disorders |
US20050119262A1 (en) * | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
-
2006
- 2006-12-18 DE DE602006008643T patent/DE602006008643D1/de active Active
- 2006-12-18 AT AT06026169T patent/ATE439863T1/de active
- 2006-12-18 EP EP06026169A patent/EP1938839B1/en active Active
- 2006-12-18 PT PT06026169T patent/PT1938839E/pt unknown
- 2006-12-18 DK DK06026169T patent/DK1938839T3/da active
- 2006-12-18 ES ES06026169T patent/ES2329161T3/es active Active
-
2007
- 2007-12-06 US US12/519,910 patent/US8524758B2/en active Active
- 2007-12-06 MX MX2009006505A patent/MX2009006505A/es active IP Right Grant
- 2007-12-06 WO PCT/IB2007/003780 patent/WO2008075149A2/en active Application Filing
- 2007-12-06 BR BRPI0720355A patent/BRPI0720355B8/pt active IP Right Grant
- 2007-12-06 JP JP2009542246A patent/JP5769375B2/ja active Active
- 2007-12-06 CA CA2672985A patent/CA2672985C/en active Active
- 2007-12-06 AU AU2007335919A patent/AU2007335919B2/en active Active
-
2013
- 2013-03-14 US US13/827,183 patent/US20130197047A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2672985C (en) | 2013-06-11 |
PT1938839E (pt) | 2009-09-30 |
AU2007335919B2 (en) | 2012-11-08 |
EP1938839B1 (en) | 2009-08-19 |
AU2007335919A1 (en) | 2008-06-26 |
US20130197047A1 (en) | 2013-08-01 |
WO2008075149A3 (en) | 2008-08-14 |
MX2009006505A (es) | 2009-09-18 |
WO2008075149A2 (en) | 2008-06-26 |
BRPI0720355B1 (pt) | 2019-02-05 |
US8524758B2 (en) | 2013-09-03 |
BRPI0720355A2 (pt) | 2013-12-31 |
JP5769375B2 (ja) | 2015-08-26 |
DE602006008643D1 (de) | 2009-10-01 |
DK1938839T3 (da) | 2009-11-30 |
CA2672985A1 (en) | 2008-06-26 |
ATE439863T1 (de) | 2009-09-15 |
ES2329161T3 (es) | 2009-11-23 |
EP1938839A1 (en) | 2008-07-02 |
US20100016395A1 (en) | 2010-01-21 |
JP2010513454A (ja) | 2010-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0720355B8 (pt) | Composições oftálmicas para o tratamento de presbiopia, bem como o uso das mesmas | |
EA200900781A1 (ru) | 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды | |
BRPI0813680A2 (pt) | AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO. | |
CR10090A (es) | Compuestos de piperazina con accion herbicida | |
ECSP109945A (es) | Nuevos herbicidas | |
CR9868A (es) | Derivados de indol 1,3-disustituido para su uso como moduladores de ppar | |
NI201100108A (es) | Nuevas pirazol - 4 - n - alcoxicarboxamidas como microbicidas. | |
BRPI0811993A2 (pt) | " hetarilanilinas como moduladores para beta-amiloide ". | |
DOP2009000134A (es) | Compuestos bicíclicos y su uso como anti-diabéticos | |
ECSP109942A (es) | Nuevos herbicidas | |
BRPI1015006A2 (pt) | uso tópico, periocular, ou intraocular de tocotrienóis para o tratamento de doenças oftálmicas | |
BRPI0508788A (pt) | tiadiazolidinonas como inibidores de sqg - 3 | |
BRPI0518169A (pt) | tiazolil-dihidro-indazóis | |
CL2009000990A1 (es) | Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras. | |
EA201000258A1 (ru) | Новые гербициды | |
CR10049A (es) | Derivados de tiadiazol como agentes antidiabéticos | |
UY31136A1 (es) | Oxazolidinonas sustituidas y su uso | |
ECSP11011245A (es) | Novedosos herbicidas | |
BRPI0911577A8 (pt) | derivados espiro-indol para o tratamento de doenças parasíticas. | |
UY31133A1 (es) | "oxazolidinonas sustituidas y su uso" | |
CO6721048A2 (es) | Anticuerpos que se unen a notum pectinacetilesterasa | |
HN2009003466A (es) | Herbicidas novedosos | |
BRPI0612471A2 (pt) | novos compostos como agonistas glp-1 | |
PA8806501A1 (es) | Triazolotriazinas y triazolopirazinas y su uso | |
SV2009003315A (es) | Nueva utilizacion para el tratamiento de las leucemias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B25C | Requirement related to requested transfer of rights |
Owner name: JORGE LUIS BENOZZI (AR) Free format text: A FIM DE ATENDER A(S) TRANSFERENCIA(S), REQUERIDA(S) ATRAVES DA PETICAO NO 870200028357DE 02/03/2020, E NECESSARIO:1. APRESENTAR DOCUMENTO QUE COMPROVE, A INTERESSADA, PODERES PARA EFETUAR O ATOPRETENDIDO, CONSIDERANDO O EXPOSTO NAS PAGINAS 20/34 E 27/34 DA PETICAO SUPRA;2. ESCLARECER A DIVERGENCIA QUE HA ENTRE A QUANTIDADE DE HERDEIRAS CONSTANTES NOSDOCUMENTOS APRESENTADOS E A PRETENSA UNICA CESSIONARIA INDICADA NA DITA PETICAO;3. APRESENTAR GRU REFERENTE AO CUMPRIMENTO DA PRESENTE EXIGENCIA. |
|
B25A | Requested transfer of rights approved | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2629 DE 25/05/2021, QUANTO AO ITEM (73) NOME DO TITULAR. |